SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): July 23, 2015

 

 

Neuralstem, Inc.

(Exact name of registrant as specified in Charter)

 

 

Delaware   000-1357459   52-2007292

(State or other jurisdiction of

incorporation or organization)

   (Commission File No.)   (IRS Employee Identification No.)

 

20271 Goldenrod Lane, 2nd Floor, Germantown, Maryland 20876

(Address of Principal Executive Offices)

 

(301) 366-4960

(Issuer Telephone number)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 8.01.Other Events.

 

On July 23, 2015 Neuralstem, Inc. (“Company”) announced that the U.S. District Court for the District of Maryland dismissed StemCells, Inc.’s patent infringement case with prejudice in favor of the Company in StemCells, Inc. v. Neuralstem, Inc. A copy of the press release, the memorandum opinion and the order of the court are attached to this report as Exhibits 99.01, 99.02 and 99.03, respectively.

 

 

Item 9.01.Financial Statement and Exhibits.

 

Exhibit

No.

  

  

Description

99.01

  

Press Release Dated July 23, 2015.

99.02

  

Memorandum Opinion.

99.03   Order of the Court.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 23, 2015 Neuralstem, Inc.
   
   
  /s/ Richard Garr  
  By: Richard Garr
  Chief Executive Officer

 

 

 

 

 
 

 

INDEX OF EXHIBITS

     

Exhibit

No.

  

  

Description

99.01   Press Release Dated July 23, 2015.
99.02   Memorandum Opinion.
99.03   Order of the Court.